April 11, 2014

NOX4 implicated in fibrosis

Genkyotex, a developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis.

Additional Info

UAB in the News

 
 
Back to Top